
Closure of Share Sale Facility for Unmarketable Parcels

Adelaide, Australia, 3 September 2021 – Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, announced today the unmarketable parcel sale facility (**UMP Facility**) for shareholders who held less than \$500 worth of fully paid ordinary shares in the Company (**Unmarketable Parcel**) has now closed as of 5.00pm (Adelaide time) Monday, 30 August 2021 (**Closing Date**).

As previously announced, based on a market close on 8 July 2021 (**Record Date**), the closing price of the Company's shares on ASX was \$0.315 and on this basis an Unmarketable Parcel was calculated to be less than 1,588 shares.

In accordance with the Company's Constitution and ASX Listing Rules, a letter and Share Retention Form was sent to all shareholders holding an Unmarketable Parcel of shares as at the Record Date of 8 July 2021 (**Eligible Shareholder**). Eligible Shareholders who wished to retain their shareholding were required to give the Company written notice by completing and returning the Share Retention Form by no later than the Closing Date or acquire additional shares or merge multiple holdings in the same name such that their holdings comprised a marketable parcel prior to the Closing Date.

Today, Nova Eye Medical confirms that 1,249 shareholders elected not to opt out of this program. These shareholders held 388,334 shares as at the Closing Date, with these shares now available for sale under the UMP Facility.

Sale proceeds will be forwarded to Eligible Shareholders as soon as practicable following settlement of all shares sold under the UMP Facility, via the payment method recorded on the Nova Eye Medical register, by either direct credit or cheque (**please see important details below**).

The sale price per share will be calculated as the volume weighted average price of every share sold on ASX under the UMP Facility. Eligible shareholders will receive a proportionate share of the sale proceeds from all shares sold under the UMP Facility.

UPDATING DIRECT CREDIT DETAILS

Nova Eye Medical strongly encourages all shareholders in Australia and New Zealand to update their Australian or New Zealand banking details online through Computershare's Investor Centre website at www.computershare.com.au/easyupdate/EYE.

Alternatively, you may contact Computershare on **1300 850 505 (within Australia)** or **+ 61 3 9415 4000 (outside Australia)**. Payment will be made in the currency of the bank account which is recorded on the register as at Friday, 10 September 2021. Your updated direct credit instructions must be received by this time, otherwise:

- For New Zealand shareholders you will need to provide your direct credit instructions in the future to claim your sale proceeds; or
- For all other shareholders, you will receive an A\$ cheque.

KEY DATES:

Event	Date
Unmarketable Parcels for which Share Retention Forms have not been received are available for sale under the UMP Facility	3 September 2021
Broker to sell remaining Unmarketable Parcels	3 September – 10 September 2021
Last Day to update credit instructions with Computershare	5.00pm (ACST, Adelaide time) on Friday 10 September 2021
Unmarketable Parcel Payment Date	As soon as practicable following settlement of all shares sold under the UMP Facility.

This release dated 3 September 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Managing Director
Nova Eye Medical Limited
W +61 417 818 658
tspurling@nova-eye.com

Investors

Dr. Tom Duthy
Investor Relations & Corporate Development
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

Media

Kate Hunt
Head of Marketing
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com